Atwa Enayat Mohamed, Nasr Mohamed Mahmoud, Ebrahim Howyda M
Dr. Atwa is a Professor of Dermatology, Venereology, and Andrology and member of the Faculty of Medicine at Zagazig University in Ash Sharqia Governorate, Egypt.
Dr. Nasr is an Associate Professor of Dermatology, Venereology, and Andrology and member of the Faculty of Medicine at Zagazig University in Ash Sharqia Governorate, Egypt.
J Clin Aesthet Dermatol. 2020 Dec;13(12):22-26. Epub 2020 Dec 1.
Intradermal botolinum toxin A (BTXA) is an advanced technique that emerged in response to the increased demand for noninvasive facial lifting and skin rejuvenation. We sought to evaluate the safety and efficacy of intradermal injections of BTXA for facial lifting. Twenty-five female patients with mild symmetrical facial skin laxity were enrolled in this study. All patients were treated with BTXA in one side of the face while the other side was injected with normal saline. The response to treatment was assessed by two dermatologists who evaluated global photographs using a quartile grading scale (QGS). The patient self-assessment and satisfaction questionnaires were recorded. A highly significant difference was found between the side injected with BTXA and the saline injected side (control) (<0.001). Facial lifting was achieved in 58.66 percent of the sides injected with BTXA. Forty-four percent of patients were very satisfied. Older patients showed better improvement than younger patients (=<0.001). The results persisted for 16 weeks. No adverse effects were observed. Our results suggest that intradermal injection of BTXA could be a safe and effective therapeutic option for face lifting.
皮内注射A型肉毒毒素（BTXA）是一种先进技术，它是为满足对面部无创提升和皮肤年轻化日益增长的需求而出现的。我们试图评估皮内注射BTXA用于面部提升的安全性和有效性。本研究纳入了25名面部皮肤轻度对称松弛的女性患者。所有患者一侧面部接受BTXA治疗，另一侧注射生理盐水。由两名皮肤科医生通过使用四分位数分级量表（QGS）评估整体照片来评估治疗反应。记录患者的自我评估和满意度问卷。注射BTXA的一侧与注射生理盐水的一侧（对照）之间发现了高度显著差异（<0.001）。注射BTXA的一侧有58.66%实现了面部提升。44%的患者非常满意。老年患者比年轻患者改善得更好（<=0.001）。结果持续了16周。未观察到不良反应。我们的结果表明，皮内注射BTXA可能是一种安全有效的面部提升治疗选择。
